Cargando…

Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations

OBJECTIVES: In a separate document, we have provided specific guidance on performing individual pharmacokinetic (PK) studies using limited samples in persons with hemophilia with the goal to optimize prophylaxis with clotting factor concentrates. This paper, intended for clinicians, aims to describe...

Descripción completa

Detalles Bibliográficos
Autores principales: Iorio, Alfonso, Edginton, Andrea N., Blanchette, Victor, Blatny, Jan, Boban, Ana, Cnossen, Marjon, Collins, Peter, Croteau, Stacy E., Fischer, Katheljin, Hart, Daniel P., Ito, Shinya, Korth‐Bradley, Joan, Lethagen, Stefan, Lillicrap, David, Makris, Mike, Mathôt, Ron, Morfini, Massimo, Neufeld, Ellis J., Spears, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6046594/
https://www.ncbi.nlm.nih.gov/pubmed/30046759
http://dx.doi.org/10.1002/rth2.12106
_version_ 1783339845537497088
author Iorio, Alfonso
Edginton, Andrea N.
Blanchette, Victor
Blatny, Jan
Boban, Ana
Cnossen, Marjon
Collins, Peter
Croteau, Stacy E.
Fischer, Katheljin
Hart, Daniel P.
Ito, Shinya
Korth‐Bradley, Joan
Lethagen, Stefan
Lillicrap, David
Makris, Mike
Mathôt, Ron
Morfini, Massimo
Neufeld, Ellis J.
Spears, Jeffrey
author_facet Iorio, Alfonso
Edginton, Andrea N.
Blanchette, Victor
Blatny, Jan
Boban, Ana
Cnossen, Marjon
Collins, Peter
Croteau, Stacy E.
Fischer, Katheljin
Hart, Daniel P.
Ito, Shinya
Korth‐Bradley, Joan
Lethagen, Stefan
Lillicrap, David
Makris, Mike
Mathôt, Ron
Morfini, Massimo
Neufeld, Ellis J.
Spears, Jeffrey
author_sort Iorio, Alfonso
collection PubMed
description OBJECTIVES: In a separate document, we have provided specific guidance on performing individual pharmacokinetic (PK) studies using limited samples in persons with hemophilia with the goal to optimize prophylaxis with clotting factor concentrates. This paper, intended for clinicians, aims to describe how to interpret and apply PK properties obtained in persons with hemophilia. METHODS: The members of the Working Party on population PK (PopPK) of the ISTH SSC Subcommittee on Factor VIII and IX and rare bleeding disorders, together with additional hemophilia and PK experts, completed a survey and ranking exercise whereby key areas of interest in the field were identified. The group had regular web conferences to refine the manuscript’s scope and structure, taking into account comments from the external feedback to the earlier document. RESULTS: Many clinical decisions in hemophilia are based on some form of explicit or implicit PK assessment. Individual patient PK profiles can be analyzed through traditional or PopPK methods, with the latter providing the advantage of fewer samples needing to be collected on any prophylaxis regimen, and without the need the for a washout period. The most useful presentation of PK results for clinical decision making are a curve of the factor activity level over time, the time to achieve a certain activity level, or related parameters like half‐life or exposure (AUC). Software platforms have been developed to deliver this information to clinicians at the point of care. Key characteristics of studies measuring average PK parameters were reviewed, outlining what makes a credible head‐to‐head comparison among different concentrates. Large data collections of PK and treatment outcomes currently ongoing will advance care in the future. CONCLUSIONS: Traditionally used to compare different concentrates, PK can support tailoring of hemophilia treatment by individual profiling, which is greatly simplified by adopting a PopPK/Bayesian method and limited sampling protocol.
format Online
Article
Text
id pubmed-6046594
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-60465942018-07-25 Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations Iorio, Alfonso Edginton, Andrea N. Blanchette, Victor Blatny, Jan Boban, Ana Cnossen, Marjon Collins, Peter Croteau, Stacy E. Fischer, Katheljin Hart, Daniel P. Ito, Shinya Korth‐Bradley, Joan Lethagen, Stefan Lillicrap, David Makris, Mike Mathôt, Ron Morfini, Massimo Neufeld, Ellis J. Spears, Jeffrey Res Pract Thromb Haemost Online‐only Articles OBJECTIVES: In a separate document, we have provided specific guidance on performing individual pharmacokinetic (PK) studies using limited samples in persons with hemophilia with the goal to optimize prophylaxis with clotting factor concentrates. This paper, intended for clinicians, aims to describe how to interpret and apply PK properties obtained in persons with hemophilia. METHODS: The members of the Working Party on population PK (PopPK) of the ISTH SSC Subcommittee on Factor VIII and IX and rare bleeding disorders, together with additional hemophilia and PK experts, completed a survey and ranking exercise whereby key areas of interest in the field were identified. The group had regular web conferences to refine the manuscript’s scope and structure, taking into account comments from the external feedback to the earlier document. RESULTS: Many clinical decisions in hemophilia are based on some form of explicit or implicit PK assessment. Individual patient PK profiles can be analyzed through traditional or PopPK methods, with the latter providing the advantage of fewer samples needing to be collected on any prophylaxis regimen, and without the need the for a washout period. The most useful presentation of PK results for clinical decision making are a curve of the factor activity level over time, the time to achieve a certain activity level, or related parameters like half‐life or exposure (AUC). Software platforms have been developed to deliver this information to clinicians at the point of care. Key characteristics of studies measuring average PK parameters were reviewed, outlining what makes a credible head‐to‐head comparison among different concentrates. Large data collections of PK and treatment outcomes currently ongoing will advance care in the future. CONCLUSIONS: Traditionally used to compare different concentrates, PK can support tailoring of hemophilia treatment by individual profiling, which is greatly simplified by adopting a PopPK/Bayesian method and limited sampling protocol. John Wiley and Sons Inc. 2018-05-20 /pmc/articles/PMC6046594/ /pubmed/30046759 http://dx.doi.org/10.1002/rth2.12106 Text en © 2018 The Authors. Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals, Inc on behalf of International Society on Thrombosis and Haemostasis. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Online‐only Articles
Iorio, Alfonso
Edginton, Andrea N.
Blanchette, Victor
Blatny, Jan
Boban, Ana
Cnossen, Marjon
Collins, Peter
Croteau, Stacy E.
Fischer, Katheljin
Hart, Daniel P.
Ito, Shinya
Korth‐Bradley, Joan
Lethagen, Stefan
Lillicrap, David
Makris, Mike
Mathôt, Ron
Morfini, Massimo
Neufeld, Ellis J.
Spears, Jeffrey
Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations
title Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations
title_full Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations
title_fullStr Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations
title_full_unstemmed Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations
title_short Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations
title_sort performing and interpreting individual pharmacokinetic profiles in patients with hemophilia a or b: rationale and general considerations
topic Online‐only Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6046594/
https://www.ncbi.nlm.nih.gov/pubmed/30046759
http://dx.doi.org/10.1002/rth2.12106
work_keys_str_mv AT iorioalfonso performingandinterpretingindividualpharmacokineticprofilesinpatientswithhemophiliaaorbrationaleandgeneralconsiderations
AT edgintonandrean performingandinterpretingindividualpharmacokineticprofilesinpatientswithhemophiliaaorbrationaleandgeneralconsiderations
AT blanchettevictor performingandinterpretingindividualpharmacokineticprofilesinpatientswithhemophiliaaorbrationaleandgeneralconsiderations
AT blatnyjan performingandinterpretingindividualpharmacokineticprofilesinpatientswithhemophiliaaorbrationaleandgeneralconsiderations
AT bobanana performingandinterpretingindividualpharmacokineticprofilesinpatientswithhemophiliaaorbrationaleandgeneralconsiderations
AT cnossenmarjon performingandinterpretingindividualpharmacokineticprofilesinpatientswithhemophiliaaorbrationaleandgeneralconsiderations
AT collinspeter performingandinterpretingindividualpharmacokineticprofilesinpatientswithhemophiliaaorbrationaleandgeneralconsiderations
AT croteaustacye performingandinterpretingindividualpharmacokineticprofilesinpatientswithhemophiliaaorbrationaleandgeneralconsiderations
AT fischerkatheljin performingandinterpretingindividualpharmacokineticprofilesinpatientswithhemophiliaaorbrationaleandgeneralconsiderations
AT hartdanielp performingandinterpretingindividualpharmacokineticprofilesinpatientswithhemophiliaaorbrationaleandgeneralconsiderations
AT itoshinya performingandinterpretingindividualpharmacokineticprofilesinpatientswithhemophiliaaorbrationaleandgeneralconsiderations
AT korthbradleyjoan performingandinterpretingindividualpharmacokineticprofilesinpatientswithhemophiliaaorbrationaleandgeneralconsiderations
AT lethagenstefan performingandinterpretingindividualpharmacokineticprofilesinpatientswithhemophiliaaorbrationaleandgeneralconsiderations
AT lillicrapdavid performingandinterpretingindividualpharmacokineticprofilesinpatientswithhemophiliaaorbrationaleandgeneralconsiderations
AT makrismike performingandinterpretingindividualpharmacokineticprofilesinpatientswithhemophiliaaorbrationaleandgeneralconsiderations
AT mathotron performingandinterpretingindividualpharmacokineticprofilesinpatientswithhemophiliaaorbrationaleandgeneralconsiderations
AT morfinimassimo performingandinterpretingindividualpharmacokineticprofilesinpatientswithhemophiliaaorbrationaleandgeneralconsiderations
AT neufeldellisj performingandinterpretingindividualpharmacokineticprofilesinpatientswithhemophiliaaorbrationaleandgeneralconsiderations
AT spearsjeffrey performingandinterpretingindividualpharmacokineticprofilesinpatientswithhemophiliaaorbrationaleandgeneralconsiderations